SEC-sourced researchBeta
STRO
SUTRO BIOPHARMA, INC.
Company comparison ↗
Data passport
- CIK
- 0001382101
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Sep 22, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 62,043,000.0000 | Mar 23, 2026 |
| December 2025 | 102,484,000.0000 | Mar 23, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 102,484,000.0000 | -191,086,000.0000 | -177,231,000.0000 | 173,830,000.0000 | 306,282,000.0000 | Mar 23, 2026 |
| December 2024 | 62,043,000.0000 | -227,461,000.0000 | -191,540,000.0000 | 387,207,000.0000 | 342,606,000.0000 | Mar 23, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $102.48M | December 2025 | Mar 23, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $62.04M | December 2024 | Mar 23, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$191.09M | December 2025 | Mar 23, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$177.23M | December 2025 | Mar 23, 2026 | 10-K |
| Total assetsAssets | $173.83M | December 2025 | Mar 23, 2026 | 10-K |
| Total liabilitiesLiabilities | $306.28M | December 2025 | Mar 23, 2026 | 10-K |